Acquisition by Eli Lilly Sigilon Therapeutics was recently acquired by Eli Lilly for $310 million, indicating a strong financial backing and potential for collaboration with Lilly's extensive network and resources.
Cell Therapy Development Sigilon is focused on developing encapsulated-cell therapies for acute and chronic diseases, such as the innovative SIG-002 treatment for type 1 diabetes, presenting a partnership opportunity for healthcare providers and institutions.
Top Talent Recruitment Sigilon has strategically hired key personnel like Sarah Yuan as Chief Technical Operations Officer, showcasing a commitment to innovation and expertise that could open avenues for partnerships and collaborations.
Funding and Financial Stability With significant funding of $145 million and reported revenues between $10-50 million, Sigilon's financial health positions the company as a potential client for service providers or investment opportunities.
Industry Partnerships The partnership between Sigilon and Eli Lilly signifies a collaborative approach to developing functional cures, making them an attractive prospect for research institutions, biotech companies, and pharmaceutical collaborators.
Sigilon Therapeutics uses 8 technology products and services including NetSuite, Exhibit, jQuery, and more. Explore Sigilon Therapeutics's tech stack below.
| Sigilon Therapeutics Email Formats | Percentage |
| First.Last@sigilon.com | 86% |
| FLast@sigilon.com | 12% |
| First@sigilon.com | 2% |
Biotechnology ResearchMassachusetts, United States51-200 Employees
Sigilon Therapeutics', a wholly owned subsidiary of Eli Lilly and Company, mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.
Company Overview
Funding & FinancialsSigilon Therapeutics has raised a total of $145M of funding over 4 rounds. Their latest funding round was raised on Dec 03, 2020 in the amount of $145M.
Sigilon Therapeutics's revenue is in the range of $10M$50M
Funding & FinancialsSigilon Therapeutics has raised a total of $145M of funding over 4 rounds. Their latest funding round was raised on Dec 03, 2020 in the amount of $145M.
Sigilon Therapeutics's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com